PLoS ONE (Jan 2016)

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

  • Vincenza Conteduca,
  • Simon J Crabb,
  • Robert J Jones,
  • Orazio Caffo,
  • Tony Elliott,
  • Emanuela Scarpi,
  • Paolo Fabbri,
  • Lisa Derosa,
  • Francesco Massari,
  • Gianmauro Numico,
  • Sunnya Zarif,
  • Catherine Hanna,
  • Francesca Maines,
  • Helen Joyce,
  • Cristian Lolli,
  • Ugo De Giorgi

DOI
https://doi.org/10.1371/journal.pone.0158952
Journal volume & issue
Vol. 11, no. 7
p. e0158952

Abstract

Read online

The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the impact of baseline NLR and its change in patients receiving enzalutamide. We included consecutive metastatic CRPC patients treated with enzalutamide after docetaxel and studies the change of NLR (>3 vs ≤3) after week 4 and 12 weeks. Progression-free survival (PFS), overall survival (OS) and their 95% Confidence Intervals (95% CI) were estimated by the Kaplan-Meier method and compared with the log-rank test. The impact of NLR on PFS and OS was evaluated by Cox regression analyses and on prostate-specific antigen response rates (PSA RR; PSA decline >50%) were evaluated by binary logistic regression. Data collected on 193 patients from 9 centers were evaluated. Median age was 73.1 years (range, 42.8-90.7). The median baseline NLR was 3.2. The median PFS was 3.2 months (95% CI = 2.7-4.2) in patients with baseline NLR >3 and 7.4 months (95% CI = 5.5-9.7) in those with NLR ≤3, p 3 and 16.9 months (95% CI = 11.2-20.9) in those with baseline NLR ≤3, p 3 during treatment with enzalutamide seems to have both prognostic and predictive value in CRPC patients.